Last update Dec. 3, 2025

Lisinopril

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary., is now set to Safe product and/or breastfeeding is the best option.

Level of risk reviewed on Dec. 3, 2025

Compatible

Safe product and/or breastfeeding is the best option.

Lisinopril is an angiotensin-converting enzyme inhibitor (ACEI) used in the treatment of hypertension, heart failure and diabetic nephropathy and as prophylaxis after myocardial infarction. Oral administration once a day.

It is excreted in breast milk in clinically insignificant amounts (Chugh 2025), and no problems have been observed in infants whose mothers took it. (Chugh 2025, Fishel 2023)

Other compounds in the same group (ACEI) are not significantly excreted in breast milk, but until further published data on this drug in relation to breastfeeding are known safer alternatives may be preferable. (Hale, LactMed, Anderson 2018, Malachias 2016)

The protective role of breastfeeding against maternal hypertension has been proven. (Park 2018)

Alternatives

We do not have alternatives for Lisinopril since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Lisinopril in other languages or writings:

Groups

Lisinopril belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Lisinopril in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 25 (6 - 60) %
Molecular weight 442 daltons
Protein Binding 0 %
VD 1.8 l/Kg
pKa 3.17 -
Tmax 7 hours
T½ 12.6 hours
Theoretical Dose 0.07 mg/Kg/d
Relative Dose 0.04 - 0.06 %

References

  1. Park S, Choi NK. Breastfeeding and Maternal Hypertension. Am J Hypertens. 2018 Abstract
  2. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  3. AEMPS. Lisinopril. Ficha técnica. 2017 Full text (in our servers)
  4. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source)
  5. Astra-Zeneca. Lisinopril. Drug Summary. 2012 Full text (in our servers)

Total visits

21,513

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM